GB 3
Alternative Names: GB-3Latest Information Update: 12 Jan 2021
At a glance
- Originator Geneva Biotech
- Class Antifibrotics; Antihyperlipidaemics
- Mechanism of Action Lipid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dyslipidaemias; Idiopathic pulmonary fibrosis
Most Recent Events
- 04 Jan 2021 GB 3 is available for licensing as of 04 Jan 2021. https://geneva-biotech.com/
- 04 Jan 2021 Preclinical trials in Dyslipidaemias in Switzerland (Geneva Biotech pipeline, January 2020)
- 04 Jan 2021 Preclinical trials in Idiopathic pulmonary fibrosis in Switzerland (Geneva Biotech pipeline, January 2020)